This is an assignment that is due Saturday June 13, 2020 by noon EST. It is a RUA medicine brochure and paper on teaching the medicine Ixekizumab. I need pictures and all! Is this something you can do? The paper needs to be written in 7th edition APA and the brochure Flesch Kincaid reading level is not higher than seventh grade level!!
Title: Teaching the Medicine Ixekizumab: An Overview and Brochure
Introduction:
Ixekizumab is a monoclonal antibody used for the treatment of moderate to severe plaque psoriasis in adults. It is a targeted therapy that specifically inhibits interleukin-17A (IL-17A), a cytokine involved in the inflammatory process of psoriasis. This paper aims to provide a comprehensive overview of Ixekizumab for healthcare professionals and patients alike. Additionally, a brochure will be developed to effectively communicate key information about Ixekizumab to a wider audience.
I. Background and Mechanism of Action:
Ixekizumab was approved by the U.S. Food and Drug Administration in 2016 for the treatment of moderate to severe plaque psoriasis. Psoriasis is a chronic autoimmune disease affecting the skin, leading to the formation of scaly red patches that can be painful and itchy. IL-17A has been identified as a key cytokine driving the inflammatory response in psoriasis. Ixekizumab, by specifically blocking IL-17A, reduces inflammation and helps improve symptoms associated with psoriasis.
II. Efficacy and Safety:
Clinical trials have demonstrated the efficacy of Ixekizumab in reducing the signs and symptoms of moderate to severe plaque psoriasis. In a randomized, controlled study, a significantly higher proportion of patients treated with Ixekizumab achieved a 75% improvement in Psoriasis Area and Severity Index (PASI 75) compared to those treated with placebo. This indicates a significant reduction in disease severity.
Adverse events associated with Ixekizumab treatment are generally mild to moderate and include upper respiratory tract infections, injection site reactions, and headache. Serious infections and hypersensitivity reactions have been reported but are rare. Patients receiving Ixekizumab should be screened for tuberculosis and monitored for signs of infection during treatment.
III. Administration and Dosage:
Ixekizumab is administered by subcutaneous injection. The recommended dosage for the treatment of plaque psoriasis is an initial dose of 160 mg (two 80 mg injections) followed by 80 mg every four weeks for maintenance. Patients can self-administer the injections after proper training and support from healthcare professionals. The injection site should be rotated to prevent injection site reactions.
IV. Monitoring and Adherence:
Regular monitoring and follow-up are important to assess treatment response, evaluate any adverse events, and ensure patient adherence to therapy. Healthcare professionals should evaluate the patient’s response to treatment after 12 weeks. If an inadequate response is observed, alternative therapies should be considered.
Patient adherence to the treatment regimen is crucial for achieving optimal outcomes. Patients should be educated about the importance of adhering to the prescribed dosing schedule and understanding the potential benefits and risks of Ixekizumab. Educational materials and counseling sessions can enhance patient understanding and adherence.
V. Patient Support:
Living with a chronic condition like psoriasis can have a significant impact on a patient’s quality of life. Patient support programs offer a range of services to help individuals effectively manage their condition. These programs may include educational resources, financial assistance, access to healthcare professionals, and psychological support.
In the brochure accompanying this paper, we have summarized key information about Ixekizumab, including its benefits, administration, potential side effects, and patient support resources. It is designed to provide clear and concise information to patients and their caregivers, ensuring that they have the necessary knowledge to make informed decisions about their treatment journey.
Conclusion:
Ixekizumab is an effective treatment option for patients with moderate to severe plaque psoriasis. Its specific targeting of IL-17A helps reduce inflammation and improve symptoms associated with psoriasis. By providing healthcare professionals and patients with accurate and accessible information about Ixekizumab, we aim to enhance the understanding and support for this therapy, ultimately improving patient outcomes and quality of life.